CIDP
18
7
7
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
5.6%
1 terminated out of 18 trials
75.0%
-11.5% vs benchmark
17%
3 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (18)
Ultrasound-driven Stratification in CIDP
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
IVIG vs SCIG in CIDP
Validation of Cutaneous Nerve Demyelination in Diagnosis and Treatment of CIDP
Vitaccess Real CIDP Registry
Biorepository and Registry for Plasma Exchange Patients
Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Electronic Monitoring of Disease Activity in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
Biomarkers in Polyradiculoneuropathies
Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation
Change of Nerve Conduction Properties in IVIg Dependent Neuropathies